|
시장보고서
상품코드
2032466
스마트 필 시장 보고서 : 대상 영역, 질환 적응증, 용도, 최종 사용자, 지역별(2026-2034년)Smart Pills Market Report by Target Area, Disease Indication, Application, End User, and Region 2026-2034 |
||||||
세계의 스마트 필 시장 규모는 2025년에 52억 달러에 이르렀습니다. 향후 IMARC Group은 2034년까지 시장 규모가 92억 달러에 이르고, 2026-2034년 CAGR 6.29%를 나타낼 것으로 예측했습니다. 고령층의 만성질환 관리에 대한 수요 증가, 급속한 기술 발전, 최소침습수술(MIS) 트렌드, 제약업계의 맞춤형 의료 및 약물 전달에 대한 관심 증가 등이 시장을 주도하는 주요 요인으로 작용하고 있습니다.
스마트 필(디지털 알약 또는 경구용 센서라고도 함)은 원격 모니터링 및 데이터 수집을 가능하게 하는 미세한 전자 부품을 탑재한 혁신적인 의약품입니다. 이 알약에는 일반적으로 센서, 마이크로칩, 송신기가 포함되어 있으며, 환자가 섭취합니다. 체내에 들어가면 체액과 상호작용하여 환자의 건강지표, 복약순응도, 생리적 반응에 대한 실시간 데이터를 외부 기기로 전송합니다. 의료진과 연구자들은 이 데이터를 활용해 환자 치료 개선, 치료 계획 최적화, 의약품 개발 개선에 활용하고 있습니다. 스마트 필은 모니터링 및 데이터 수집 기능을 강화함으로써 맞춤형 의료, 만성 질환 관리 및 임상시험에서 잠재적인 이점을 제공합니다.
세계 고령화에 따른 만성질환 유병률 증가와 환자의 건강 상태를 지속적으로 모니터링하고 관리할 필요성이 높아지면서 세계 스마트 필 시장은 괄목할 만한 성장세를 보이고 있습니다. 스마트 필은 비침습적이고 효율적인 실시간 건강 데이터 수집을 위한 비침습적 수단을 제공하여 원격 환자 모니터링 및 질병 관리의 귀중한 도구가 되고 있습니다. 또한, 소형 전자기기와 무선 통신 기술의 발전으로 스마트 필의 개발 및 제조 비용이 절감되고, 의료진과 환자가 보다 쉽게 사용할 수 있게 되면서 시장 확대에 대한 전망이 밝아지고 있습니다. 이와 더불어 맞춤형 의료에 대한 수요 증가와 정밀한 약물 전달 시스템에 대한 요구가 높아지면서 제약사 및 연구자들이 스마트 필 기술에 대한 투자를 진행하고 있으며, 이는 시장 성장에 기여하고 있습니다. 또한, COVID-19 팬데믹으로 인해 원격 의료 및 원격 모니터링 솔루션의 도입이 가속화되면서 스마트 필 시장이 더욱 활성화되고 있습니다.
스마트 필 시장 동향과 촉진요인:
고령화와 만성질환 관리
중요한 촉진요인 중 하나는 세계 고령화의 진행입니다. 인구의 평균 연령이 증가함에 따라 당뇨병, 고혈압, 심혈관 질환 등 만성질환의 유병률도 증가하고 있습니다. 이러한 질환을 관리하기 위해서는 지속적인 모니터링과 복약 순응도가 필수적입니다. 스마트 필은 환자의 건강 지표에 대한 비침습적 실시간 데이터 수집을 제공함으로써 혁신적인 솔루션을 제공합니다. 이 원격 모니터링 기능은 기존의 모니터링 방법으로는 어려움을 겪을 수 있는 고령의 환자들에게 특히 유용합니다. 의료진은 스마트 필의 데이터를 활용하여 적시에 개입하고, 치료 계획을 조정하고, 더 나은 질병 관리를 보장함으로써 노인 케어의 질을 향상시킬 수 있습니다.
지속적인 기술 발전
소형 전자기기, 센서 및 무선 통신 기술의 발전은 스마트 필 시장의 성장에 크게 기여하고 있습니다. 이러한 기술적 진보로 인해 더 작고 삼키기 쉬운 스마트 필이 개발되어 환자의 편의성과 복약 순응도를 높이고, 복용 시 불편함과 저항감을 줄일 수 있게 되었습니다. 또한, 부품의 소형화는 제조 비용을 절감했을 뿐만 아니라 스마트 필의 전반적인 효율성과 내구성을 향상시켰습니다. 그 결과, 의료진과 환자들은 보다 접근하기 쉽고 비용 효율적인 솔루션의 혜택을 누릴 수 있게 되었습니다. 또한, 스마트 필을 통해 수집되는 데이터의 정확성과 신뢰성이 높아지면서 의료계 내 수용도가 높아져 시장 확대에 기여하고 있습니다.
맞춤형 의료와 새로운 약물 전달 시스템에 대한 수요 증가
제약업계의 맞춤형 의료 및 정밀 약물 전달 시스템에 대한 관심이 높아지는 것도 또 다른 촉진제 역할을 하고 있습니다. 스마트 필은 체내 표적 부위에 직접 약물을 투여하는 독자적인 수단을 제공합니다. 이 표적 지향적 약물 전달은 부작용을 최소화하면서 치료 효과를 높일 수 있습니다. 제약사들은 환자 개개인의 니즈에 맞는 의약품 개발을 실현하기 위한 수단으로 스마트 필 기술에 대한 투자를 확대되고 있습니다. 또한, 스마트 필은 임상시험에서 약물의 효과에 대한 실시간 데이터를 수집하는 데 활용할 수 있어 조사 방법을 효율화하고 새로운 치료법 시장 도입을 가속화할 수 있는 잠재력을 가지고 있습니다.
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 주요 요약
제4장 서론
제5장 세계의 스마트 필 시장
제6장 시장 분석 : 대상 영역별
제7장 시장 분석 : 질환 적응증별
제8장 시장 분석 : 용도별
제9장 시장 분석 : 최종 사용자별
제10장 시장 분석 : 지역별
제11장 SWOT 분석
제12장 밸류체인 분석
제13장 Porter's Five Forces 분석
제14장 가격 분석
제15장 경쟁 구도
JHS 26.05.18The global smart pills market size reached USD 5.2 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 9.2 Billion by 2034, exhibiting a growth rate (CAGR) of 6.29% during 2026-2034. The increased demand for chronic disease management among the geriatric population, rapid technological advancements, emerging trend of minimally invasive surgeries (MIS), the increasing focus of pharmaceutical industry on personalized medicine and drug delivery are some of the major factors propelling the market.
Smart pills, also known as digital pills or ingestible sensors, are innovative pharmaceuticals equipped with tiny electronic components that enable remote monitoring and data collection. These pills typically contain sensors, microchips, and transmitters, which are ingested by patients. Once inside the body, they interact with bodily fluids, sending real-time data about a patient's health metrics, medication adherence, and physiological responses to external devices. Healthcare providers and researchers use this data to enhance patient care, optimize treatment plans, and improve drug development. Smart pills offer potential benefits in personalized medicine, chronic disease management, and clinical trials by enhancing monitoring and data acquisition capabilities.
The global smart pills market is experiencing substantial growth driven by the aging population across the globe has resulted in an increased prevalence of chronic diseases, requiring continuous monitoring and management of patient's health. Smart pills offer a non-invasive and efficient way to collect real-time health data, making them a valuable tool for remote patient monitoring and disease management. Moreover, advancements in miniaturized electronics and wireless communication technologies have made it more cost-effective to develop and produce smart pills, increasing their accessibility to healthcare providers and patients, which is creating a positive outlook for market expansion. In addition to this, the rising demand for personalized medicine and the need for precise drug delivery systems prompting pharmaceutical companies and researchers to invest in smart pill technology, are contributing to the market growth. Furthermore, the COVID-19 pandemic has fueled the adoption of telehealth and remote monitoring solutions, further boosting the market for smart pills.
SMART PILLS MARKET TRENDS/DRIVERS:
Aging population and chronic disease management
One significant driver is the increasing geriatric population across the globe. As the average age of the population rises, so does the prevalence of chronic diseases such as diabetes, hypertension, and cardiovascular diseases. Managing these conditions often requires continuous monitoring and medication adherence. Smart pills provide an innovative solution by offering non-invasive, real-time data collection on a patient's health metrics. This remote monitoring capability is particularly valuable for elderly patients who may have difficulty with conventional monitoring methods. Healthcare providers can use the data from smart pills to make timely interventions, adjust treatment plans, and ensure better disease management, improving the quality of care for aging populations.
Ongoing technological advancements
Advancements in miniaturized electronics, sensors, and wireless communication technologies have significantly contributed to the growth of the smart pills market. These technological strides have led to the development of smaller, more easily ingestible smart pills, enhancing patient comfort and compliance while reducing the potential for discomfort or resistance during ingestion. Moreover, the miniaturization of components has not only reduced manufacturing costs but also improved the overall efficiency and longevity of smart pills. As a result, healthcare providers and patients benefit from more accessible and cost-effective solutions, while the enhanced accuracy and reliability of the data collected by smart pills have garnered increased acceptance within the medical community, aiding in market expansion.
Growing demand for personalized medicine and novel drug delivery
The pharmaceutical industry's growing interest in personalized medicine and precise drug delivery systems is another driving factor. Smart pills offer a unique way to administer medications directly to the target site in the body. This targeted drug delivery can enhance the efficacy of treatments while minimizing side effects. Pharmaceutical companies are increasingly investing in smart pill technology as a means to improve drug development, ensuring that medications are tailored to individual patient needs. Apart from this, smart pills can be used in clinical trials to gather real-time data on the drug's effects, streamlining the research process and potentially speeding up the introduction of new therapies to the market.
SMART PILLS INDUSTRY SEGMENTATION:
Breakup by Target Area:
- Esophagus
- Small Intestine
- Large Intestine
- Stomach
Small intestine dominate the market
The demand for smart pills targeting the small intestine is propelled by their unique ability to access and monitor this specific area of the digestive tract. The small intestine plays a crucial role in nutrient absorption, making it a focal point for various gastrointestinal disorders and drug delivery challenges. Smart pills designed to operate in this region offer precise insights into nutrient absorption efficiency, allowing for tailored dietary recommendations and treatments for conditions, such as malabsorption syndromes. Furthermore, their application extends to drug delivery optimization, ensuring medications reach the intended site of action, which is especially relevant for treatments that require absorption in the small intestine. As a result, the demand for smart pills tailored to the small intestine continues to rise, driven by their potential to address specific healthcare needs and enhance therapeutic outcomes.
Breakup by Disease Indication:
- Esophageal Diseases
- Small Bowel Diseases
- Colon Diseases
- Others
The surging demand for smart pills in addressing esophageal, small bowel, and colon diseases owing to their capacity to provide precise, real-time data in these specific areas of the gastrointestinal tract is strengthening the market growth. Moreover, the growing prevalence of esophageal diseases such as gastroesophageal reflux disease (GERD), wherein smart pills help monitor pH levels and track acid reflux patterns, aiding in the diagnosis and management of these conditions. Apart from this, in small bowel diseases like Crohn's disease or celiac disease, these pills can help track the passage and transit time, enabling clinicians to assess motility and inflammation, while in colon diseases, particularly colorectal cancer screening, smart pills equipped with imaging capabilities can capture detailed images, enhancing early detection and reducing the need for invasive procedures. This targeted monitoring and diagnostic potential are propelling the demand for smart pills in the context of esophageal, small bowel, and colon diseases, improving patient care and outcomes.
Breakup by Application:
- Capsule Endoscopy
- Drug Delivery
- Patient Monitoring
Capsule endoscopy dominate the market
Unlike traditional endoscopy, smart pills equipped with imaging technology provide a painless and patient-friendly alternative for visualizing the gastrointestinal tract. This has led to increased acceptance and patient compliance, especially in cases where traditional endoscopy may be uncomfortable or challenging. Additionally, capsule endoscopy using smart pills is particularly valuable for diagnosing and monitoring conditions such as obscure gastrointestinal bleeding, Crohn's disease, and small bowel tumors. The high-quality images and real-time data captured by these smart pills allow for early detection and precise localization of abnormalities, thereby facilitating timely interventions and improving patient outcomes. Consequently, the demand for smart pills in capsule endoscopy continues to grow, enhancing the diagnostic capabilities of healthcare professionals and patient experiences.
Breakup by End User:
- Hospitals
- Diagnostic Centers
- Research Institutes
Diagnostic centers hold the largest share in the market
The rising demand for smart pills in diagnostic centers is bolstering market expansion by offering a patient-friendly, non-invasive approach to enhance diagnostic procedures. These devices provide real-time gastrointestinal data, aiding precise diagnoses, especially for conditions like gastrointestinal bleeding, motility disorders, and small bowel diseases. Smart pills' imaging capabilities, pH assessment, and transit monitoring provide clinicians with a comprehensive view of GI health, reducing the need for uncomfortable invasive procedures. This improves patient comfort, compliance, and diagnostic accuracy, benefiting both patients and healthcare providers, and contributing to the growing adoption of smart pills in diagnostic centers.
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
North America exhibits a clear dominance, accounting for the largest smart pills market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
North America's robust healthcare infrastructure, including advanced diagnostic centers and research institutions, is facilitating the adoption of smart pills for innovative diagnostic and research purposes. Concurrently, the increasing prevalence of gastrointestinal disorders, such as inflammatory bowel disease and colorectal cancer, has created a high demand for non-invasive diagnostic tools like smart pills, which offer improved patient comfort and compliance. Moreover, the region's aging population, with a growing need for chronic disease management, sees smart pills as an invaluable solution for remote patient monitoring. Besides this, favorable reimbursement policies and regulatory frameworks in North America are encouraging healthcare providers and pharmaceutical companies to invest in smart pill technology. Apart from this, the region's technological innovation and early market entry by leading companies have established a strong foundation for the growth of the North America smart pills market.
COMPETITIVE LANDSCAPE:
The global smart pills market presents a competitive landscape characterized by a mix of established players and emerging entrants striving to capitalize on the growing demand for remote patient monitoring and innovative healthcare solutions. Leading companies hold substantial market shares, primarily due to their early market entry, robust R&D capabilities, and extensive distribution networks. They offer a diverse range of smart pill products, incorporating advanced sensor technologies and data analytics platforms. Moreover, partnerships and collaborations with healthcare providers and pharmaceutical companies have further solidified their market position. At the same time, numerous startups and smaller companies, are actively contributing to market growth with disruptive technologies and novel applications of smart pills, intensifying competition and driving innovation in the industry.
The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:
- CapsoVision Inc
- Check-Cap Ltd.
- General Electric Company
- IntroMedic Co. Ltd.
- Jinshan Science & Technology (Group) Co. Ltd.
- Koninklijke Philips N.V.
- Medtronic plc
- Olympus Corporation
- PENTAX Medical (Hoya Corporation).
KEY QUESTIONS ANSWERED IN THIS REPORT
- How has the global smart pills market performed so far, and how will it perform in the coming years?
- What are the drivers, restraints, and opportunities in the global smart pills market?
- What is the impact of each driver, restraint, and opportunity on the global smart pills market?
- What are the key regional markets?
- Which countries represent the most attractive smart pills market?
- What is the breakup of the market based on the target area?
- Which is the most attractive target area in the smart pills market?
- What is the breakup of the market based on the disease indication?
- Which is the most attractive disease indication in the smart pills market?
- What is the breakup of the market based on the application?
- Which is the most attractive application in the smart pills market?
- What is the breakup of the market based on the end user?
- Which is the most attractive end user in the smart pills market?
- What is the competitive structure of the global smart pills market?
- Who are the key players/companies in the global smart pills market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Smart Pills Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Target Area
- 6.1 Esophagus
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Small Intestine
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Large Intestine
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Stomach
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
7 Market Breakup by Disease Indication
- 7.1 Esophageal Diseases
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Small Bowel Diseases
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Colon Diseases
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Others
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
8 Market Breakup by Application
- 8.1 Capsule Endoscopy
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Drug Delivery
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Patient Monitoring
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
9 Market Breakup by End User
- 9.1 Hospitals
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Diagnostic Centers
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Research Institutes
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.1.1 United States
- 10.2 Asia-Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.2.1 China
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.3.1 Germany
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.4.1 Brazil
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 CapsoVision Inc.
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.2 Check-Cap Ltd.
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.2.3 Financials
- 15.3.3 General Electric Company
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.3.3 Financials
- 15.3.3.4 SWOT Analysis
- 15.3.4 IntroMedic Co. Ltd.
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.4.3 Financials
- 15.3.5 Jinshan Science & Technology (Group) Co. Ltd.
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.6 Koninklijke Philips N.V.
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.6.3 Financials
- 15.3.6.4 SWOT Analysis
- 15.3.7 Medtronic plc
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.7.3 Financials
- 15.3.7.4 SWOT Analysis
- 15.3.8 Olympus Corporation
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.8.3 Financials
- 15.3.8.4 SWOT Analysis
- 15.3.9 PENTAX Medical (Hoya Corporation)
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.1 CapsoVision Inc.
